Fate Therapeutics (FATE) Misses Q2 EPS by 5c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.58), $0.05 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $6.31 million.

“We are very pleased with the early clinical safety and activity we have observed with our off-the-shelf, iPSC-derived NK cell programs in relapsed / refractory lymphoma and acute myeloid leukemia, where interim Phase 1 data indicate FT516 and FT538 are well tolerated and can deliver complete responses for patients. We look forward to sharing additional clinical data from our FT516 and FT596 programs in B-cell lymphoma at our upcoming investor event,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “Additionally, treatment of the first patient with FT819, the first-ever iPSC-derived T-cell therapy to undergo clinical investigation, is a landmark achievement and further demonstrates the Company’s leadership in off-the-shelf, iPSC-derived cell therapy and the versatility of its proprietary iPSC Product Platform.”

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• Associated Banc-Corp (ASB) Tops Q1 EPS by 3c